Home > Insider Trading > Filing (0000899243-21-036429)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1863127	Tyra Biosciences Inc.	TYRA	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1198325	Daniel Janney	C/O Alta Partners Nextgen Fund Ii Manage 115 W Snow King Ave, Suite 101B Jackson WY 83001	No	No	Yes	No
1674884	A Peter Hudson	C/O Alta Partners Nextgen Fund Ii Manage 115 W Snow King Ave, Suite 101B Jackson WY 83001	No	No	Yes	No
1768658	Alta Partners Nextgen Fund Ii, L.p.	115 W Snow King Ave, Suite 101B Jackson WY 83001	No	No	Yes	No
1881002	Alta Partners Nextgen Fund Ii Management, Llc	115 W Snow King Ave, Suite 101B Jackson WY 83001	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-09-17	3,811,117	$0.00	3,924,046	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-09-17	156,250	$16.00	4,080,296	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2021-09-17	1,212,122	$0.00	3,148,365	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-09-17	255,160	$0.00	662,752	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer.
These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC ("APNG II Management"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports.